Marea Therapeutics, a clinical-stage biotechnology company has secured $190M combined Series A and B Funding. The Series A round was led by Third Rock Ventures and the Series B round was led by Sofinnova Investments and co-led by Forbion, Perceptive Xontogeny Venture Fund and venBio, with the participation of Alpha Wave Global, Omega Funds, Surveyor Capital and founding investor Third Rock Ventures.
Read also – [Funding News] TX-based Trustwise Raises $4 Mn Seed Funding
This financing for the Marea Therapeutics will fund the Phase 2 development plan of MAR001 and further progress other pipeline programmes.
Read also – [Funding News] Aptatek BioSciences Secures Undisclosed Funding
“Marea aims to transform the way cardiometabolic diseases are treated by leveraging large-scale human genetics and expertise in adipose function and biology to pursue genetically validated targets focusing on central – but unaddressed – drivers of cardiometabolic disease risk,” said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. “This approach could be the next frontier for patients with cardiometabolic disease who remain at very high risk, despite currently available therapies.”
“With initial clinical validation, world-class scientific founders and investors, and an experienced board and leadership team, Marea is poised to become a premier cardiometabolic disease company,” said Jeffrey Tong, Ph.D., board member and partner, Third Rock Ventures. “We aim to accelerate a new generation of medicines, including MAR001, that treat key unaddressed drivers of cardiometabolic disease, potentially providing important new therapeutic options for millions of patients.”
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The Marea Therapeutics’s lead program, MAR001, is in Phase 2 clinical development and has the potential to become a new treatment for patients who remain at high risk of severe cardiovascular disease due to elevated remnant cholesterol and metabolic dysfunction.
